191 related articles for article (PubMed ID: 23784600)
1. [Aspirin and prevention of colorectal carcinomas].
Schrör K; Rauch BH
Internist (Berl); 2013 Jul; 54(7):884-91. PubMed ID: 23784600
[TBL] [Abstract][Full Text] [Related]
2. [Aspirin in primary and secondary prevention of colorectal carcinomas].
Schrör K; Rauch B
Med Monatsschr Pharm; 2013 Nov; 36(11):411-21. PubMed ID: 24640118
[TBL] [Abstract][Full Text] [Related]
3. Aspirin and colorectal cancer: back to the future.
Tougeron D; Sha D; Manthravadi S; Sinicrope FA
Clin Cancer Res; 2014 Mar; 20(5):1087-94. PubMed ID: 24327271
[TBL] [Abstract][Full Text] [Related]
4. [Aspirin in the prevention of colorectal cancer].
Zubiaurre L; Bujanda Fernández de Pierola L
Gastroenterol Hepatol; 2011 May; 34(5):337-45. PubMed ID: 21435744
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer.
Schrör K
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):473-84. PubMed ID: 22122764
[TBL] [Abstract][Full Text] [Related]
6. Theoretical investigation of aspirin dosage regimen to exhibit optimal antiplatelet effects and decrease risk of upper gastrointestinal lesions.
Yokoyama H; Yaguchi T; Suzuki Y; Tokuoka K; Watanabe M; Kitagawa Y; Yamada Y
Biol Pharm Bull; 2012; 35(12):2112-8. PubMed ID: 23047244
[TBL] [Abstract][Full Text] [Related]
7. Aspirin use and survival after diagnosis of colorectal cancer.
Chan AT; Ogino S; Fuchs CS
JAMA; 2009 Aug; 302(6):649-58. PubMed ID: 19671906
[TBL] [Abstract][Full Text] [Related]
8. Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer.
Patrignani P; Sacco A; Sostres C; Bruno A; Dovizio M; Piazuelo E; Di Francesco L; Contursi A; Zucchelli M; Schiavone S; Tacconelli S; Patrono C; Lanas A
Clin Pharmacol Ther; 2017 Jul; 102(1):52-61. PubMed ID: 28139830
[TBL] [Abstract][Full Text] [Related]
9. A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker.
Sample D; Wargovich M; Fischer SM; Inamdar N; Schwartz P; Wang X; Do KA; Sinicrope FA
Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):275-9. PubMed ID: 11895877
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.
Hull MA; Sandell AC; Montgomery AA; Logan RF; Clifford GM; Rees CJ; Loadman PM; Whitham D
Trials; 2013 Jul; 14():237. PubMed ID: 23895505
[TBL] [Abstract][Full Text] [Related]
11. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
Gill S; Sinicrope FA
Semin Oncol; 2005 Feb; 32(1):24-34. PubMed ID: 15726503
[TBL] [Abstract][Full Text] [Related]
12. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.
Flossmann E; Rothwell PM;
Lancet; 2007 May; 369(9573):1603-13. PubMed ID: 17499602
[TBL] [Abstract][Full Text] [Related]
13. Can We Select Patients for Colorectal Cancer Prevention with Aspirin?
Kraus S; Sion D; Arber N
Curr Pharm Des; 2015; 21(35):5127-34. PubMed ID: 26369678
[TBL] [Abstract][Full Text] [Related]
14. Post-study aspirin intake and factors motivating participation in a colorectal cancer chemoprevention trial.
Sample DA; Sinicrope PS; Wargovich MJ; Sinicrope FA
Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):281-5. PubMed ID: 11895878
[TBL] [Abstract][Full Text] [Related]
15. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.
Cole BF; Logan RF; Halabi S; Benamouzig R; Sandler RS; Grainge MJ; Chaussade S; Baron JA
J Natl Cancer Inst; 2009 Feb; 101(4):256-66. PubMed ID: 19211452
[TBL] [Abstract][Full Text] [Related]
16. Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer.
Benamouzig R; Uzzan B; Little J; Chaussade S
Curr Top Med Chem; 2005; 5(5):493-503. PubMed ID: 15974944
[TBL] [Abstract][Full Text] [Related]
17. Aspirin for cancer is no mere antiplatelet prototype. There is potential in its ancient roots.
Lawrence JR; Baxter GJ; Paterson JR
Med Hypotheses; 2016 Sep; 94():74-6. PubMed ID: 27515206
[TBL] [Abstract][Full Text] [Related]
18. The role of aspirin in colorectal cancer chemoprevention.
Singh Ranger G
Crit Rev Oncol Hematol; 2016 Aug; 104():87-90. PubMed ID: 27289249
[TBL] [Abstract][Full Text] [Related]
19. Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer.
Krishnan K; Ruffin MT; Normolle D; Shureiqi I; Burney K; Bailey J; Peters-Golden M; Rock CL; Boland CR; Brenner DE
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):447-53. PubMed ID: 11352853
[TBL] [Abstract][Full Text] [Related]
20. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.
Rothwell PM; Wilson M; Elwin CE; Norrving B; Algra A; Warlow CP; Meade TW
Lancet; 2010 Nov; 376(9754):1741-50. PubMed ID: 20970847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
